在B型肝炎患者中,循环血栓素2作为肝细胞癌的预测因子,这些患者接受了核胺模拟疗法
Taiki Okumura1,2, Takefumi Kimura3,4, Yuki Ichikawa1,5
1Division of Gastroenterology and Hepatology, Department of Medicine, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano, 390-8621, Japan.
Scientific reports
|October 27, 2024
概括
在慢性乙型肝炎患者中,核胺类同类疗法降低了血清血栓素2 (TSP2) 水平. 更高的TSP2水平预测了未来肝细胞癌 (HCC) 的发展,这表明TSP2是潜在的HCC生物标志物.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 生物标志物发现发现
- 在瘤学瘤学.
背景情况:
- 血栓素2 (TSP2) 对于血管和结缔组织功能至关重要.
- 以前的研究将血清TSP2与非酒精性脂肪肝和C型肝炎的肝病严重程度联系起来.
- TSP2在慢性乙型肝炎 (CHB) 进展和肝癌发生中的作用尚不清楚.
研究的目的:
- 调查血清TSP2在CHB患者中的临床意义.
- 在肝脏组织学和抗病毒治疗期间评估血清TSP2水平.
- 为了确定血清TSP2是否可以预测肝细胞癌 (HCC) 在接受核酸类比 (NA) 治疗的CHB患者的发展.
主要方法:
- 87名CHB患者的横截面分析 (研究1),将血清TSP2与临床病理参数相关联.
- 51名CHB患者在NA治疗期间血清TSP2变化和HCC发展的长度随访 (研究2) 平均7.5年.
- 统计分析包括相关性,纵向变化和卡普兰-梅尔对HCC发展的生存分析.
主要成果:
- 在研究1中,血清TSP2水平与门口炎症或纤维化没有显著的关联.
- 在研究2中,在NA治疗48周后,血清TSP2水平显著下降 (P<0.001).
- 在NA治疗48周后的TSP2水平 (TSP2-48W) 在患有HCC的患者中明显高于未患有HCC的患者 (P = 0.043).
- 较高的TSP2-48W (≥24 ng/mL) 与未来的HCC发展有显著的关联 (P = 0.030).
结论:
- 在CHB患者的NA疗法下,血清TSP2水平降低.
- 在NA治疗期间血清TSP2水平升高可能作为HCC发展的预测生物标志物.
- 需要进一步的前性研究来验证TSP2在接受NA治疗的CHB患者中作为HCC预测因子.
相关概念视频
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
01:25Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
01:23Cirrhosis I: Introduction
Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
01:24Cirrhosis II: Pathophysiology
Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...